The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Also known as: CBC, CBC includes Differential and Platelets, CBC/PLT w/DIFF, Complete Blood Count (includes Differential and Platelets)
NOTE: Ulta Lab Tests provides CBC test results from Quest Diagnostics as they are reported. Often, different biomarker results are made available at different time intervals. When reporting the results, Ulta Lab Tests denotes those biomarkers not yet reported as 'pending' for every biomarker the test might report. Only biomarkers Quest Diagnostics observes are incorporated and represented in the final CBC test results provided by Ulta Lab Tests.
Also known as: Chem 12, Chemistry Panel, Chemistry Screen, CMP, Complete Metabolic Panel, Comprehensive Metabolic Panel CMP, SMA 12, SMA 20
Also known as: A1c, Glycated Hemoglobin, Glycohemoglobin, Glycosylated Hemoglobin, HA1c, HbA1c, Hemoglobin A1c, Hemoglobin A1c HgbA1C, Hgb A1c
Also known as: Iron and TIBC, Iron and Total Iron Binding Capacity TIBC, TIBC
Also known as: Lipid Panel with Ratios (fasting), Lipid Profile with Ratios (fasting), Lipids
Also known as: Reverse T3, Reverse Triiodothyronine, RT3, T3 Reverse RT3 LCMSMS, Triiodothyronine Reverse
Also known as: Triiodothyronine
Also known as: Free T3, FT3, T3 Free
Also known as: T4 Thyroxine Total
Also known as: Free T4, FT4, T4 Free
Also known as: Thyroid Stimulating Hormone, Thyroid Stimulating Hormone (TSH), Thyrotropin
Also known as: Thyroid Receptor Antibody, Thyroid Stimulating Immunoglobulin, TSI Thyroid Stimulating Immunoglobulin
Also known as: B12, B12 Vitamin, Cobalamin, Cyanocobalamin, Vitamin B12 Cobalamin
Also known as: B6, B6 Vitamin, Pyridoxal, Pyridoxal Phosphate, Pyridoxal Phosphate (PLP), Vitamin B6 Pyridoxal Phosphate
The TH-4. Graves Disease panel contains 17 tests with 84 biomarkers.
Brief Description: The TH-4 Graves' Disease panel is a sophisticated and comprehensive set of diagnostic tests specifically designed to assess Graves' disease, an autoimmune disorder leading to hyperthyroidism. This panel not only evaluates thyroid hormone levels and autoimmune markers but also examines the broader systemic effects of the disease on metabolic health, nutritional status, and potential comorbid conditions.
Collection Method: Blood Draw
Specimen Type: Whole Blood, Serum, and Plasma
Test Preparation: Patient should be fasting 9-12 hours prior to collection.
Patient must be restricted from alcohol and vitamins for at least 24 hours before a sample collection.
Collection should be done in the morning.
Specifc to TSH: Specimen collection after fluorescein dye angiography should be delayed for at least 3 days. For patients on hemodialysis, specimen collection should be delayed for 2 weeks.
According to the assay manufacturer Siemens: "Samples containing fluorescein can produce falsely depressed values when tested with the Advia Centaur TSH3 Ultra assay."
Healthcare providers order the TH-4 Graves' Disease panel for individuals presenting with symptoms indicative of hyperthyroidism, such as weight loss, palpitations, anxiety, and heat intolerance, particularly when Graves' disease is suspected. This panel is crucial for diagnosing Graves' disease, differentiating it from other thyroid disorders, monitoring the progression and response to treatment, and assessing the overall health impact of the disease.
The TH-4 Graves' Disease panel is specifically designed to diagnose and manage Graves' disease. It also helps in identifying and managing potential complications and related conditions such as osteoporosis, cardiovascular diseases, and diabetes, which can be associated with or exacerbated by hyperthyroidism.
Healthcare professionals use the results of the TH-4 Graves' Disease panel to diagnose Graves' disease, assess the severity of hyperthyroidism, evaluate the autoimmune response, and monitor the effectiveness of treatment. The comprehensive nature of the panel also allows for the identification and management of complications and associated conditions, ensuring a holistic approach to patient care.
The TH-4 Graves' Disease panel offers an extensive evaluation of Graves' disease, providing critical insights into thyroid function, autoimmune status, and the broader health impacts of thyroid dysfunction. By combining thyroid function tests with assessments for autoimmune markers, metabolic health, and nutritional status, this panel enables healthcare providers to develop targeted treatment strategies, addressing the complexities of Graves' disease and enhancing patient outcomes.
We advise having your results reviewed by a licensed medical healthcare professional for proper interpretation of your results.